Evidence map›Paper›PMID 31731679›Full record

ArticleMolecules (Basel, Switzerland)2019

Facile Synthesis of Novel Prussian Blue-Lipid Nanocomplexes.

Maria Antònia Busquets, Ariadna Novella-Xicoy, Valeria Guzmán, Joan Estelrich

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maria Antònia BusquetsPharmacy and Pharmaceutical Technology and, Physical Chemistry Department, Faculty of Pharmacy and Food Sciences, University of Barcelona, Avda. Joan XXIII, 27-31, 08028 Barcelona, Catalonia, Spain.ORCID 0000-0002-6232-9886
Ariadna Novella-XicoyPharmacy and Pharmaceutical Technology and, Physical Chemistry Department, Faculty of Pharmacy and Food Sciences, University of Barcelona, Avda. Joan XXIII, 27-31, 08028 Barcelona, Catalonia, Spain.
Valeria GuzmánDepartment of Biotechnology, Polytechnic University of Sinaloa, Carretera Municipal Libre Mazatlán Higueras Km 3, 82199 Mazatlán, Sinaloa, Mexico.
Joan EstelrichPharmacy and Pharmaceutical Technology and, Physical Chemistry Department, Faculty of Pharmacy and Food Sciences, University of Barcelona, Avda. Joan XXIII, 27-31, 08028 Barcelona, Catalonia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prussian blue (PB) is known for its multiple applications ranging from fine arts to therapeutics. More recently, PB nanoparticles have been pointed to as appealing photothermal agents (PA) when irradiated with wavelengths corresponding to the biological windows, namely regions located in the near infrared (NIR) zone. In addition, the combination of PB with other components such as phospholipids boosts their therapeutical potential by facilitating, for instance, the incorporation of drugs becoming suitable drug delivery systems. The novelty of the research relies on the synthesis procedure and characterization of hybrid lipid-PB nanoparticles with a high yield in a friendly environment suitable for photothermal therapy. This goal was achieved by first obtaining insoluble PB coated with oleylamine (OA) to facilitate its combination with lipids. The resulting lipid-PB complex showed a monomodal distribution of sizes with an overall size of around 100 nm and a polydispersity index of about 0.200. It highlights one critical step in the synthesis procedure that is the shaking time of the mixture of PB-OA nanoparticles with the lipid, which was found to be 48 h. This time assured homogeneous preparation without the need of further separation stages. Samples were stable for more than three months under several storage conditions.

Indexed as

Drug Delivery SystemsFerrocyanidesHumansLipidsNanoparticlesferric ferrocyanideFerrocyanidesLipidslipid nanoparticlesNIRphotothermal agentphotothermal therapyPrussian blue nanoparticles

Identifiers

PMID31731679
PMCPMC6891449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.